340B Program Savings Calculator: How Much Is Your FQHC Leaving on the Table? (2026)
The 340B Drug Pricing Program is the single largest cost-reduction lever available to FQHCs, disproportionate share hospitals, and other covered entities. When run correctly, it can cut drug acquisition costs by 25% to 50% across your entire formulary. When run poorly, or when eligible prescriptions slip through the cracks, you leave hundreds of thousands of dollars on the table every year.
We built this guide to answer a straightforward question: how much should your entity be saving through 340B, and how does that compare to what you are actually capturing? Below, we break down the pricing mechanics, walk through savings benchmarks by drug category and entity size, and provide an inline calculator so you can estimate your own projected savings in under two minutes.
What is the 340B ceiling price, and how does it compare to WAC?
Before you can estimate savings, you need to understand the two prices that define the 340B discount window.
WAC (Wholesale Acquisition Cost) is the manufacturer's published list price to wholesalers. Think of it as the sticker price. It does not include rebates, prompt-pay discounts, or any negotiated reductions. WAC is what a non-340B entity pays before any additional purchasing agreements kick in.
The 340B ceiling price is the maximum price a manufacturer can charge a covered entity. HRSA calculates it using this formula:
AMP (Average Manufacturer Price): the average price paid to manufacturers by retail pharmacies for drugs distributed to the retail class of trade.
URA (Unit Rebate Amount): the basic Medicaid rebate, calculated as the greater of 23.1% of AMP (for brand drugs) or AMP minus best price.
For generics and OTC drugs, the URA equals 13% of AMP.
The gap between WAC and the 340B ceiling price is where your savings live. For a brand-name drug with a WAC of $500 per month, the 340B ceiling price might be $275, producing $225 per fill in savings. For a generic with a WAC of $15, the ceiling price might be $12.75, saving $2.25 per fill. The percentage discount is smaller on generics, but the volume is much higher.
HRSA publishes 340B ceiling prices quarterly through a secure database available only to registered covered entities. If your pharmacy team is not checking these prices against what your wholesaler actually charges, you may be overpaying even within the 340B framework. Wholesaler markups above ceiling price are a compliance violation, but they do happen, particularly on drugs with recent price changes.
340B savings by drug category: what the numbers actually look like
Savings rates vary widely by drug category. The table below shows typical discount ranges based on published HRSA data, 340B Prime Vendor pricing, and aggregate FQHC reporting from 2025 and early 2026.
| Drug Category | Typical WAC Range | 340B Discount Range | Annual Savings per 100 Rx/mo |
|---|---|---|---|
| Generics | $4 - $80/fill | 10% - 20% | $4,800 - $19,200 |
| Brand-name | $50 - $800/fill | 25% - 50% | $15,000 - $480,000 |
| Specialty | $1,000 - $15,000/fill | 30% - 60% | $360,000 - $10,800,000 |
| Biosimilars | $500 - $5,000/fill | 20% - 45% | $120,000 - $2,700,000 |
| Insulin | $100 - $600/fill | 25% - 55% | $30,000 - $396,000 |
| HIV/Hepatitis | $1,500 - $4,000/fill | 35% - 60% | $630,000 - $2,880,000 |
Two things stand out in this data. First, specialty drugs and HIV/Hepatitis medications produce outsized savings on a per-prescription basis. An FQHC dispensing just 20 specialty prescriptions per month can generate more 340B revenue than 500 generic prescriptions combined. Second, the discount ranges are wide because the 340B ceiling price depends on manufacturer-specific AMP and rebate calculations, not a flat percentage.
If you are curious how these 340B prices compare to what cash-pay patients see at retail pharmacies, RxGrab's breakdown of generic vs. brand-name pricing shows the retail side of the equation. The gap between retail and 340B is even wider than the gap between WAC and 340B. For clinicians counseling patients on supplement use alongside 340B-dispensed medications, Health Britannica's evidence-based supplement guides cover interaction considerations for common drug classes.
Annual savings projections by entity size
Your total 340B savings depend on three variables: monthly prescription volume, formulary mix (the ratio of generics to brand to specialty), and capture rate (the percentage of eligible prescriptions actually purchased at 340B pricing). Here are benchmarks by entity size, assuming a 75% capture rate and a typical FQHC formulary mix of 70% generic, 20% brand, and 10% specialty.
| Entity Size | Monthly Rx Volume | Est. Monthly Drug Spend (WAC) | Est. Annual 340B Savings |
|---|---|---|---|
| Small FQHC (1-2 sites) | 500 - 1,500 | $75,000 - $250,000 | $180,000 - $600,000 |
| Mid-size FQHC (3-8 sites) | 1,500 - 5,000 | $250,000 - $900,000 | $600,000 - $2,400,000 |
| Large FQHC (9+ sites) | 5,000 - 20,000 | $900,000 - $4,000,000 | $2,400,000 - $12,000,000 |
| DSH Hospital | 10,000 - 50,000 | $2,000,000 - $15,000,000 | $5,000,000 - $40,000,000 |
| Children's Hospital | 3,000 - 15,000 | $800,000 - $5,000,000 | $2,000,000 - $15,000,000 |
These numbers assume a blended savings rate of approximately 20% on generics, 35% on brand-name drugs, and 45% on specialty drugs. Your actual results will shift based on your specific formulary. An entity with a higher proportion of HIV patients, for example, will see savings well above these averages because antiretroviral drugs carry some of the deepest 340B discounts in the program.
The capture rate problem: where most FQHCs lose money
The single biggest driver of underperformance in 340B programs is not pricing. It is capture rate. Capture rate measures the percentage of 340B-eligible prescriptions that are actually purchased at 340B pricing. The national average for FQHCs hovers around 65% to 70%. Top-performing programs exceed 85%.
That gap represents real money. For a mid-size FQHC spending $500,000 per month on drugs, the difference between a 65% capture rate and an 85% capture rate is roughly $360,000 in additional annual savings. That is an extra $30,000 per month falling through the cracks.
Common causes of low capture rates:
- Incomplete patient eligibility screening. If your intake process does not verify 340B eligibility at every visit, prescriptions for eligible patients get filled at standard pricing. This is the most common leakage point.
- Claims matching failures. The prescription must be linked to an eligible patient encounter at a registered 340B site. If your EHR and pharmacy system do not communicate cleanly, eligible claims get missed.
- Contract pharmacy gaps. Patients who fill prescriptions at non-contract pharmacies generate zero 340B savings, even if they are fully eligible. Expanding your contract pharmacy network (where manufacturer restrictions allow) captures prescriptions that would otherwise be lost.
- Manufacturer restrictions. Since 2020, over a dozen manufacturers have imposed restrictions on contract pharmacy replenishment. If your compliance team is not tracking these restrictions in real time, you may be purchasing drugs at WAC that should be at 340B pricing, or worse, failing to submit replenishment claims.
- Split billing errors. Entities using the replenishment model must accurately track which prescriptions were dispensed to 340B-eligible patients. Errors in the split billing process lead to either missed savings (under-claiming) or compliance violations (over-claiming).
Healthcare finance leaders who want a broader framework for evaluating cost-reduction strategies can reference CeoCult's overview of healthcare business finance, which covers margin optimization beyond the pharmacy department.
340B savings calculator: estimate your annual program value
Enter your monthly drug spend and prescription volume below. The calculator applies category-specific discount rates and your estimated capture rate to project annual 340B savings. These are estimates based on national benchmarks, not guarantees. Your actual savings depend on your specific formulary, payer mix, and operational execution.
340B Savings Estimator
A few notes on interpreting your results. The calculator uses midpoint discount rates (15% for generics, 37.5% for brand, 45% for specialty). Your actual discounts will vary drug by drug. The "potential additional savings at 85% capture" line shows what you would gain by improving your capture rate to 85%, which is achievable for most FQHCs with proper technology and workflow optimization.
Real examples: what mid-size FQHCs are actually saving
Abstract percentages are useful for planning. Concrete examples make the case to your board. Here are three anonymized FQHC profiles based on published program data from HRSA and 340B Health's 2025 annual survey.
Profile 1: Urban FQHC, 4 sites, 2,800 Rx/month
Monthly drug spend at WAC: $420,000. Formulary mix: 65% generic, 22% brand, 13% specialty. This entity serves a large HIV-positive population, which inflates the specialty percentage. At a 78% capture rate, their annual 340B savings total $1,680,000. Their largest single savings line item is tenofovir/emtricitabine (generic Truvada), which alone accounts for $340,000 in annual savings.
Profile 2: Rural FQHC, 2 sites, 900 Rx/month
Monthly drug spend at WAC: $110,000. Formulary mix: 78% generic, 18% brand, 4% specialty. Limited specialty volume due to smaller patient panel and fewer complex-care patients. At a 70% capture rate, annual 340B savings total $280,000. This entity identified $65,000 in additional capturable savings by adding a contract pharmacy relationship with a regional chain, bringing their effective capture rate to 79%.
Profile 3: Suburban FQHC, 6 sites, 4,200 Rx/month
Monthly drug spend at WAC: $680,000. Formulary mix: 68% generic, 24% brand, 8% specialty. Growing diabetes population driving increased insulin and GLP-1 spend. At an 82% capture rate, annual 340B savings total $2,100,000. This entity reinvests 40% of 340B savings into expanded behavioral health services, a common and HRSA-encouraged use of 340B program revenue.
The pattern across all three: specialty drugs punch above their weight. Even at 4% to 13% of prescription volume, specialty medications generate 30% to 50% of total 340B savings. If your entity is not actively managing its specialty drug pipeline, that is the first place to look for improvement.
How to increase your 340B capture rate
Improving capture rate is the highest-ROI activity in 340B program management. Every percentage point of improvement translates directly to additional savings, with zero increase in drug spending. Here is the priority sequence, ordered by typical impact.
1. Automate eligibility verification. Manual eligibility checks at patient intake miss prescriptions. A system that automatically cross-references patient encounters with prescription claims, and flags mismatches in real time, can increase capture rates by 8 to 15 percentage points. This is the single highest-impact change most FQHCs can make.
2. Tighten EHR-to-pharmacy data integration. If your EHR and pharmacy management system require manual data entry or batch file transfers, claims will fall through the cracks. Real-time HL7/FHIR integration between systems eliminates the most common source of matching errors.
3. Audit your contract pharmacy network quarterly. Manufacturer restrictions change frequently. At least once per quarter, review which manufacturers are restricting your contract pharmacy arrangements, and adjust your purchasing and claims submission processes accordingly. Missing a restriction change can result in both lost savings and compliance exposure.
4. Train front-desk and clinical staff on 340B eligibility triggers. Every patient encounter at a registered site generates potential 340B eligibility. Staff who understand which visit types qualify (and which do not) can flag edge cases that automated systems might miss.
5. Track actual vs. projected savings monthly. If your 340B administrator cannot produce a monthly report showing projected savings (based on eligible prescription volume) versus actual savings (based on 340B purchases), you have a visibility problem. OmniRx's compliance dashboard generates this comparison automatically, flagging months where actual savings fall more than 10% below projection so you can investigate the gap before it compounds.
The difference between a well-run and a poorly-run 340B program is not the pricing. HRSA sets that. It is the operational discipline to capture every eligible prescription, verify every claim match, and catch every manufacturer restriction change before it costs you money.
Contract pharmacy restrictions: the 2024-2026 landscape
The biggest structural change to 340B economics in the past three years has been manufacturer-imposed contract pharmacy restrictions. As of early 2026, 32 manufacturers have implemented some form of restriction, up from 17 in 2023. These restrictions take several forms:
- Single contract pharmacy limitation: The manufacturer will honor 340B pricing at only one contract pharmacy per covered entity. Entities with multiple contract pharmacy relationships must choose which one receives 340B pricing for that manufacturer's drugs.
- Claims-level data requirements: Some manufacturers require covered entities to submit detailed claims-level data (patient ID, prescription details, dispense date) to a third-party administrator before honoring 340B pricing. The administrative burden is significant.
- Complete refusal: A small number of manufacturers have stopped offering 340B pricing through contract pharmacies entirely, limiting 340B access to the entity's in-house pharmacy only.
For FQHCs that rely heavily on contract pharmacies (which is most of them, since many lack a full in-house pharmacy), these restrictions have reduced 340B savings by 20% to 40% on affected drugs. The legal landscape is still shifting. HRSA has issued an Administrative Dispute Resolution rule, and multiple lawsuits are working through federal courts. But in the meantime, covered entities need a system that tracks manufacturer-specific restrictions in real time and adjusts purchasing workflows automatically.
When evaluating the retail price impact of these restrictions, RxGrab's analysis of insurance vs. cash pricing provides useful context on how drug pricing works on the patient-facing side of the equation.
Split billing vs. replenishment: which model captures more savings?
Covered entities use one of two inventory management models for 340B. The choice affects both compliance risk and savings capture efficiency.
Replenishment model: The pharmacy maintains a single inventory. When a 340B-eligible prescription is dispensed, the entity "replenishes" that unit by purchasing a replacement at the 340B ceiling price. This is the more common model (used by roughly 70% of entities) because it is simpler operationally. The risk: if your claims matching is imprecise, you may replenish more or fewer units than you actually dispensed to eligible patients. Over-replenishment is a compliance violation. Under-replenishment means lost savings.
Split billing model: The pharmacy maintains two separate virtual inventories: one purchased at 340B pricing, one at WAC. Prescriptions are routed to the appropriate inventory at the point of dispense. This model is more precise but requires tighter system integration and real-time eligibility determination. Entities using split billing typically achieve 3 to 5 percentage points higher capture rates because the eligibility check happens before dispensing, not after.
Neither model is universally superior. Small entities with simple operations often do better with replenishment because it requires less infrastructure. Larger entities with robust pharmacy IT typically achieve better results with split billing. What matters more than the model is whether your systems can accurately match prescriptions to eligible encounters. A well-implemented replenishment model outperforms a poorly-implemented split billing model every time.
How to benchmark your 340B program
Once you have run the calculator above, compare your results to these national benchmarks published by 340B Health and NACHC (National Association of Community Health Centers).
| Metric | Below Average | Average | Top Quartile |
|---|---|---|---|
| Capture rate | < 60% | 65% - 75% | > 85% |
| Blended savings rate | < 18% | 22% - 30% | > 35% |
| Savings per Rx | < $8 | $12 - $25 | > $35 |
| 340B revenue as % of total | < 5% | 8% - 15% | > 20% |
| Compliance audit findings (annual) | 5+ | 1 - 3 | 0 |
If your entity falls below average on capture rate or blended savings rate, start with the improvement sequence outlined above. If you are average but want to reach the top quartile, the marginal gains come from specialty drug optimization, contract pharmacy expansion (where restrictions allow), and monthly variance tracking.
Frequently asked questions
How much does the 340B program save FQHCs on average?
Most FQHCs save between 25% and 50% on total drug acquisition costs through 340B pricing. The exact figure depends on your payer mix, formulary composition, and how aggressively you capture eligible prescriptions. A mid-size FQHC filling 3,000 prescriptions per month typically saves $400,000 to $1.2 million annually.
What is the difference between WAC and 340B ceiling price?
WAC (Wholesale Acquisition Cost) is the manufacturer's list price to wholesalers before any discounts. The 340B ceiling price is the maximum price manufacturers can charge covered entities, calculated as AMP minus the Unit Rebate Amount (URA). For brand-name drugs, the 340B ceiling price is typically 25% to 50% below WAC. For generics, the discount is smaller (10% to 20%) because generic WAC prices are already lower.
Which drug categories produce the largest 340B savings?
Specialty drugs produce the largest absolute savings, with discounts of 30% to 60% off WAC. A single specialty drug like adalimumab can save your entity $20,000 or more per patient per year. Brand-name drugs follow at 25% to 50% discounts. Generics offer the smallest percentage discounts (10% to 20%) but still contribute meaningful volume savings because they represent the majority of prescriptions filled.
Can contract pharmacies participate in 340B savings?
Yes, covered entities can use contract pharmacies to dispense 340B drugs to eligible patients. However, several manufacturers now restrict contract pharmacy arrangements, requiring claims-level data or limiting distribution to a single contract pharmacy per entity. These restrictions have reduced contract pharmacy savings by 20% to 40% for many FQHCs since 2022.
How do I know if my FQHC is maximizing 340B savings?
Compare your actual savings rate against national benchmarks: FQHCs should capture 340B pricing on 70% or more of eligible prescriptions. If your capture rate is below 60%, you are likely leaving significant savings on the table. Common leakage points include missed patient eligibility screening, incomplete claims matching, and underutilized contract pharmacy networks.
The bottom line
- 340B savings range from 10% to 60% depending on drug category. Specialty drugs and HIV medications produce the deepest discounts.
- Capture rate is the controllable variable. Most FQHCs operate at 65% to 75% capture. Moving to 85% can add $200,000 or more in annual savings for a mid-size entity.
- Contract pharmacy restrictions are real and growing. 32 manufacturers now limit contract pharmacy 340B access. Your compliance system must track these in real time.
- The calculator above gives you a baseline. Run your numbers, compare to the benchmarks table, and identify which improvement lever (capture rate, specialty optimization, contract pharmacy expansion) has the highest ROI for your entity.
- Monthly variance tracking between projected and actual savings is the fastest way to catch problems before they compound into six-figure losses.
Get 340B savings benchmarks and compliance updates
We publish monthly analysis of 340B pricing changes, manufacturer restrictions, and FQHC savings benchmarks.